Latest Cancer Treatment News

Page 10 of 10
Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.
Ada Torres
Ada Torres
30 Apr 2025
Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.
Victor Sage
Victor Sage
11 Feb 2025
AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.
Ada Torres
Ada Torres
7 Feb 2025
OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.
Victor Sage
Victor Sage
4 Feb 2025
Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.
Victor Sage
Victor Sage
31 Jan 2025
Invion Limited has marked significant progress in its cancer treatment pipeline, dosing the first patient in a pivotal skin cancer trial and reporting encouraging prostate cancer results, while securing fresh funding to support ongoing development.
Victor Sage
Victor Sage
31 Jan 2025
Amplia Therapeutics has completed enrolment for its ACCENT Phase 2a trial in advanced pancreatic cancer two months early, reporting encouraging partial response rates and improved patient outcomes.
Victor Sage
Victor Sage
31 Jan 2025
Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.
Ada Torres
Ada Torres
31 Jan 2025
OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.
Victor Sage
Victor Sage
30 Jan 2025
Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.
Ada Torres
Ada Torres
29 Jan 2025
OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.
Victor Sage
Victor Sage
28 Jan 2025